Crinetics Pharmaceuticals, Inc. (FRA:6Z4)

Market Cap	3.44B +53.2%
Revenue (ttm)	6.55M +640.7%
Net Income	-396.31M
EPS	-4.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	32.36
Previous Close	32.54
Day's Range	32.36 - 32.36
52-Week Range	23.00 - 43.40
Beta	n/a
RSI	49.77
Earnings Date	May 7, 2026

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida...

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 594
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6Z4

Financial Performance

In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.

Financial numbers in USD